Bionano Genomics (BNGO) Registration filing summary

Company overview and business model

• Provides optical genome mapping (OGM) systems, consumables, software, diagnostic testing and nucleic-acid purification solutions for research, clinical and bioprocessing applications.

• Saphyr and Stratys systems detect structural variation; VIA integrates OGM, next-generation sequencing and microarray data for genomic analysis and interpretation.

• Bionano Laboratories offers OGM-based FSHD1 testing and laboratory services; certain NDD, hematologic malignancy and pre-/postnatal testing services were phased out during 2024–2025.

• Strategy emphasizes cost savings and greater utilization of the installed OGM base, with less focus on new system placements.

Financial performance and metrics

• Going-concern uncertainty: ability to continue operations within 12 months of the Q2 2026 10-Q filing depends on cost management and significant additional financing.

• Common stock closed at $1.16 on October 26, 2026; 13,976,957 shares were outstanding as of October 23, 2026.

Use of proceeds and capital allocation

• Full exercise of the warrants would generate estimated gross proceeds of ~$90 million; no proceeds arise from subsequent sales of the underlying shares.

• Net proceeds, together with existing cash, cash equivalents and available-for-sale securities, are intended for general corporate purposes, including working capital, R&D and capital expenditures.

• Exercise timing and scale are uncertain; management has broad discretion over allocation, and proceeds pending use would be invested in short-term, interest-bearing instruments.